Privacy policy
1. Definitions and Interpretation
2. Data Collected
- 2.1 name;
- 2.2 date of birth;
- 2.3 job title & profession;
- 2.4 contact information such as email addresses and telephone numbers;
- 2.5 demographic information such as post code, preferences and interests;
- 2.6 financial information such as credit / debit card numbers;
- 2.7 IP address (automatically collected);
- 2.8 web browser type and version (automatically collected);
- 2.9 operating system (automatically collected);
- 2.10 a list of URLS starting with a referring site, your activity on this Web Site, and the site you exit to (automatically collected); and
- 2.11 Cookie information (see Clause 10 below).
3. Our Use of Data
- 3.1 Any personal Data you submit will be retained by Iridium CE for as long as you use the Services and Systems provided on the Web Site. Data that you may submit through any communications System that we may provide may be retained for a longer period of up to one year.
- 3.2 Unless we are obliged or permitted by law to do so, and subject to Clause 4, your Data will not be disclosed to third parties. This includes our affiliates and / or other companies within our group.
- 3.3 All personal Data is stored securely in accordance with the principles of the Data Protection Act 1998. For more details on security, see Clause 9 below.
- 3.4 Any or all of the above Data may be required by us from time to time in order to provide you with the best possible service and experience when using our Web Site. Specifically, Data may be used by us for the following reasons:
- 3.4.1 internal record keeping;
- 3.4.2 improvement of our products / services;
- 3.4.3 transmission by email of promotional materials that may be of interest to you;
- 3.4.4 contact for market research purposes which may be done using email, telephone, fax or mail. Such information may be used to customise or update the Web Site.
4. Third Party Web Sites and Services
5. Changes of Business Ownership and Control
- 5.1 Iridium CE may, from time to time, expand or reduce its business and this may involve the sale of certain divisions or the transfer of control of certain divisions to other parties. Data provided by Users will, where it is relevant to any division so transferred, be transferred along with that division and the new owner or newly controlling party will, under the terms of this Policy, be permitted to use the Data for the purposes for which it was supplied by you.
- 5.2 In the event that any Data submitted by Users will be transferred in such a manner, you will be contacted in advance and informed of the changes. When contacted you will be given the choice to have your Data deleted or withheld from the new owner or controller.
6. Controlling Access to your Data
- 6.1 Wherever you are required to submit Data, you will be given options to restrict our use of that Data. This may include the following:
- 6.1.1 use of Data for direct marketing purposes; and
- 6.1.2 sharing Data with third parties.
7. Your Right to Withhold Information
- 7.1 You may access certain areas of the Web Site without providing any Data at all. However, to use all Services and Systems available on the Web Site you may be required to submit Account information or other Data.
- 7.2 You may restrict your internet browser’s use of Cookies. For more information see Clause 10 below.
8. Accessing your own Data
- 8.1 You may access your Account at any time to view or amend the Data. You may need to modify or update your Data if your circumstances change. Additional Data as to your marketing preferences may also be stored and you may change this at any time.
- 8.2 You have the right to ask for a copy of your personal Data on payment of a small fee.
9. Security
10. Changes to this Policy
11. Contacting Us

Legal

Stay Informed
We appreciate your ongoing interest and look forward to keeping you informed with the latest details!
Thank you for confirming.
You’ll receive reminder emails for the next LGS CME/CE session, including full access details.
We look forward to your participation.
Earn up to 1.5 AMA PRA Credit
The OX2R Era Is Here. Is Your NT1 Diagnosis?
Phoenix, AZ | October 18, 2026 | 12:00 - 1:15 Phoenix Time
Learning Objectives
- Identify the full NT1 symptom pentad and the systemic clinical burden of orexin deficiency.
- Apply the cataplexy interrogation question at the CPAP non-response encounter.
- Differentiate NT1 from NT2, idiopathic hypersomnia, and common misdiagnoses using the defining diagnostic criterion of cataplexy or CSF hypocretin-1 <110 pg/mL.
- Distinguish NT1 from medication-induced and primary psychiatric EDS using ICSD-3 criteria when psychiatric comorbidity complicates evaluation of excessive daytime sleepiness.
- Apply evidence-based PSG/MSLT diagnostic protocols, including medication washout requirements, SOREMP interpretation, and CSF hypocretin-1 <110 pg/mL as a standalone NT1 diagnostic criterion per ICSD-3.
- Integrate SDoH-informed screening, navigator referral pathways, and telehealth-compatible approaches to reduce diagnostic delay in NT1 across diverse patient populations.
- Individualize NT1 treatment selection using an SDM framework informed by the limitations of current pharmacotherapy and the mechanism of emerging OX2R-directed therapies.
Accredited Provider


Joint Accreditation Statement

Physician Credit Designation
Nurse Contact Hours Designation
Global Education Group designates this continuing education activity for 1.5 contact hour(s) including 0.0 pharmacotherapeutic contact hour(s).
Faculty, Staff, and Planners’ Disclosures
Disclosure of Unlabeled Use
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosures of Relevant Financial Relationship(s)
The faculty have the following relevant financial relationships with ineligible companies:
Disclosures
University of California
La Jolla, CA
Disclosures
Volunteer Peer Support Group Facilitator, Wake Up Narcolepsy Oklahoma City, Oklahoma
Disclosures
Instructions to Receive Credit
A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.
Fee Information and Refund/Cancellation Policy
Global Contact Information
System Requirements
Program Overview
Target Audience
The primary audience for this activity includes pulmonologists, sleep specialists, primary care physicians, internists, hospitalists, nurse practitioners, physician assistants, and respiratory therapists involved in the diagnosis and management of narcolepsy.
Supporter Acknowledgement
Use of artificial intelligence in this activity
How the AI is controlled.
The AI does not search the internet. It does not give you diagnostic or treatment recommendations. Before release, the faculty and the IridiumCE and Global Education Group planners, tested the simulation for accuracy, completeness, balance and freedom from commercial bias on October 12, 2026.
Platform: Patient dialogue is generated using OpenAI's GPT-4.1 model (gpt-4.1-2025-04-14). The patient's video avatar is powered by HeyGen.
Independence. Global, as the accredited provider, is responsible for all content in this activity, including what the AI generates.
Data. All conversation and scores are recorded so we can give personalized feedback, award credit, and evaluate and improve the activity.
Pre-Meeting Simulation: The OX2R Era Is Here. Is Your NT1 Diagnosis?
AI Simulation: The OX2R Era Is Here. Is Your NT1 Diagnosis?